Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Starpharma Holdings Limited ( (AU:SPL) ) has provided an announcement.
Starpharma Holdings Limited announced a change in the director’s interest notice, revealing that Cheryl Maley, a director, has experienced a lapse of 439,752 performance rights due to unmet performance criteria. This adjustment in director’s interests reflects internal performance evaluations and may impact the company’s governance and stakeholder confidence.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
More about Starpharma Holdings Limited
Starpharma Holdings Limited operates in the pharmaceutical industry, focusing on innovative products such as dendrimer-based therapeutics and other healthcare solutions.
YTD Price Performance: 209.09%
Average Trading Volume: 945,573
Technical Sentiment Signal: Hold
Current Market Cap: A$142.2M
Find detailed analytics on SPL stock on TipRanks’ Stock Analysis page.